Study guide
4.3 Statistical Analysis & Risk Quantification
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
4.3 Statistical Analysis & Risk Quantification
Key Takeaways Explain This Topic AI
Relative risk (RR) measures prospective incidence ratios in cohort studies and RCTs, whereas the odds ratio (OR) is used in case-control studies and approximates RR only when the disease is rare (< 5%–10% prevalence).
Absolute risk reduction (ARR = CER - EER) reflects real-world clinical impact, and its reciprocal is the number needed to treat (NNT = 1 / ARR), which must always be rounded up to the next integer.
Type I error (alpha) is the probability of a false positive (rejecting H0 when true), while Type II error (beta) is a false negative; statistical power equals 1 - beta (conventionally >= 80%).
A 95% confidence interval for a difference is statistically significant (p < 0.05) if it excludes 0, whereas a 95% confidence interval for a ratio (RR, OR, HR) is significant if it excludes 1.0.
Parametric tests (t-test, ANOVA) require normally distributed continuous data; non-parametric equivalents (Mann-Whitney U, Kruskal-Wallis) analyze ranked or skewed data.
Last updated: September 2026
Note
Curriculum Focus : Risk calculations and statistical test selection are among the highest-yield topics in the MRCP(UK) Part 1 examination. Candidates must be fluent in calculating Absolute Risk Reduction (ARR), Number Needed to Treat (NNT), Number Needed to Harm (NNH), and Odds Ratios from 2x2 data tables, as well as interpreting 95% confidence intervals and selecting correct parametric versus non-parametric statistical tests.
Evidence-based clinical decision-making requires accurate quantification of therapeutic benefit and harm. A physician must be able to decipher whether a reported drug benefit reflects a transformative absolute risk reduction or merely a modest relative improvement inflated by clinical reporting.
Measures of Disease Frequency
Epidemiology measures how frequently disease occurs in populations using three primary metrics:
1. Prevalence
Definition : The proportion of individuals in a specified population who have the disease at a defined point in time:
Prevalence = Existing Cases (Old + New) / Total Population at Risk
Characteristics : A dimensionless proportion (ranging from 0 to 1, or 0% to 100%). It reflects a single cross-sectional snapshot.
Prevalence Relationship : Prevalence is a function of both incidence and disease duration:
Prevalence ≈ Incidence x Average Disease Duration A drug that improves survival in a chronic disease without curing it (e.g., insulin in type 1 diabetes) increases disease prevalence by prolonging duration.
2. Cumulative Incidence (Incidence Proportion / Risk)
Definition : The proportion of initially disease-free individuals who develop the disease over a specified time horizon:
Cumulative Incidence = New Cases Developing During Follow-up / Population at Risk at Baseline
Limitation : Assumes all participants are observed for the entire study interval; cannot account for individuals who enter late or drop out.
3. Incidence Rate (Incidence Density)
Definition : The rate at which new events arise per unit of person-time at risk:
Incidence Rate = New Cases Developing During Follow-up / Total Person-Time at Risk (e.g., person-years)
Advantage : Accommodates varying lengths of patient follow-up, staggered trial enrollment, and censoring (death, loss to follow-up).
Risk Quantification Formulas
In a clinical trial or prospective cohort study, subjects are classified into experimental and control arms, yielding a standard 2x2 contingency table:
- Cohort Group Event Occurred (+) Event Did Not Occur (-) Total Group Size
- Experimental / Intervention a b a + b
- Control / Placebo c d c + d
- Core Mathematical Formulations
- 1. Experimental Event Rate (EER) and Control Event Rate (CER)
- Control Event Rate : CER = c / (c + d)
- Experimental Event Rate : EER = a / (a + b)
- 2. Relative Risk (Risk Ratio, RR)
Formula :
Relative Risk = EER / CER = [a / (a + b)] / [c / (c + d)]
Application : Cohort studies and randomized controlled trials (where true incidence can be measured directly).
Interpretation :
RR = 1.0: No difference in risk between groups.
RR < 1.0: Intervention reduces risk (protective effect).
RR > 1.0: Intervention or exposure increases risk.
3. Odds Ratio (OR)
Formula :
Odds Ratio = (Odds of Exposure in Cases) / (Odds of Exposure in Controls) = (a / c) / (b / d) = (a x d) / (b x c)
Application : Case-control studies (where background population denominators are unknown).
The Rare Disease Assumption : When the baseline disease prevalence is low (< 5%–10%), a is negligible relative to b, and c is negligible relative to d. Under these conditions, the Odds Ratio closely approximates the Relative Risk (OR ≈ RR). If the condition is common (> 10%), the OR significantly exaggerates the relative risk.
4. Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR)
Absolute Risk Reduction (Risk Difference) :
ARR = CER - EER
Relative Risk Reduction :
RRR = ARR / CER = (CER - EER) / CER = 1 - RR
Absolute Risk Increase (ARI) : When the experimental arm produces higher adverse events:
ARI = EER - CER
Important
The RRR Deception : Pharmaceutical literature frequently highlights RRR because it yields impressive numbers. If a drug reduces event risk from 2% to 1%, the RRR is 50% , but the ARR is only 1% . Clinical impact is determined by ARR, not RRR.
Number Needed to Treat (NNT) and Harm (NNH)
The Number Needed to Treat (NNT) represents the average number of patients who must receive the specific intervention over a defined duration to prevent one additional adverse clinical event :
- NNT = 1 / Absolute Risk Reduction (ARR) = 1 / (CER - EER)
- NNH = 1 / Absolute Risk Increase (ARI) = 1 / (EER - CER)
- The Three Golden Rules of NNT for MRCP(UK)
Always express ARR as a decimal before inverting :
If ARR = 4%, write as 0.04. NNT = 1 / 0.04 = 25.
Never divide 1 by 4 (which yields 0.25)!
Always round UP to the next whole integer :
If a calculation yields an NNT of 14.2, the answer is 15 , not 14. Treating 14 patients leaves the 15th partially unprevented; to ensure one full event is averted, 15 patients must be treated.
Conversely, for NNH , round DOWN (e.g., 18.8 -> 18) to provide a conservative, prudent estimate of harm.
Always link NNT to a time frame :
An NNT of 25 over 6 months represents a vastly different clinical commitment than an NNT of 25 over 10 years.
Worked Example: Statin Primary Prevention
In a 5-year randomized trial of hypercholesterolaemic patients:
- Control Group 5-year MI incidence: 8.0% (CER = 0.08)
- Statin Group 5-year MI incidence: 5.2% (EER = 0.052)
- Absolute Risk Reduction : ARR = 0.08 - 0.052 = 0.028 (2.8%)
- Relative Risk Reduction : RRR = 0.028 / 0.08 = 35%
- Number Needed to Treat : NNT = 1 / 0.028 = 35.71 -> 36 patients treated for 5 years
- Hypothesis Testing, Inferential Errors & Power
Statistical hypothesis testing evaluates whether observed clinical differences reflect genuine biological effects or random sampling variation.
The Hypotheses
Null Hypothesis (H0) : There is no genuine difference between study groups; any observed disparity is due to chance alone.
Alternative Hypothesis (H1) : There is a true difference between study groups.
Type I and Type II Errors
Reality \ Decision Reject Null Hypothesis (H0) Fail to Reject Null Hypothesis (H0)
H0 is Actually True ; (No real effect) Type I Error (alpha) ; False Positive (False alarm) Correct Decision ; Probability = 1 - alpha (Specificity)
H0 is Actually False ; (True effect exists) Correct Decision ; Statistical Power (1 - beta) Type II Error (beta) ; False Negative (Missed effect)
Type I Error (alpha) : Rejecting the null hypothesis when it is actually true. The threshold is conventionally set at alpha = 0.05 (5%) . A p-value < 0.05 indicates that if the null hypothesis were true, there is less than a 5% probability of observing an effect this large purely by chance.
Type II Error (beta) : Failing to reject the null hypothesis when a true difference actually exists. Conventionally set at beta = 0.10 to 0.20 (10%–20%) .
Statistical Power (1 - beta) : The probability of correctly detecting a true difference if one exists. High-quality trials target a power of 80% or 90% (0.80 or 0.90).
Determinants of Statistical Power
Power increases when:
Sample size increases (n increases).
True effect size increases (larger ARR or difference between means).
Measurement variability / standard deviation decreases (more homogeneous population).
Significance threshold is relaxed (increasing alpha from 0.01 to 0.05).
- P-Values versus 95% Confidence Intervals
- P-Values
A p-value quantifies the probability of obtaining data at least as extreme as observed, assuming the null hypothesis is correct. It provides a continuous measure of evidence against H0, but does not indicate effect magnitude, precision, or clinical relevance.
95% Confidence Intervals (CI)
A 95% confidence interval provides a range within which the true population parameter lies with 95% certainty across repeated sampling experiments.
The Critical Rules of Confidence Interval Interpretation +------------------------------------------------------------------------------------------+
- | Confidence Interval Significance Rules |
- +------------------------------------------------------------------------------------------+
- | 1. For DIFFERENCES (Mean Difference, Risk Difference, ARR): |
- | • Null value = 0 (Zero) |
- | • If 95% CI DOES NOT span 0 --> Statistically Significant (p < 0.05) |
- | • If 95% CI SPANS 0 (e.g., -1.2 to +4.5) --> NOT Statistically Significant (p >= 0.05)|
- | |
- | 2. For RATIOS (Relative Risk, Odds Ratio, Hazard Ratio): |
- | • Null value = 1.0 (One) |
- | • If 95% CI DOES NOT span 1.0 --> Statistically Significant (p < 0.05) |
- | • If 95% CI SPANS 1.0 (e.g., 0.82 to 1.45) --> NOT Statistically Significant (p >= 0.05|
- +------------------------------------------------------------------------------------------+
- Statistical vs Clinical Significance
Large Sample Size Trap : An overpowered trial (n = 40,000) may demonstrate a statistically significant reduction in systolic blood pressure of 0.4 mmHg (95% CI 0.1 to 0.7 mmHg; p = 0.008). While statistically significant, it is clinically irrelevant.
Small Sample Size Trap (Underpowered) : A small trial (n = 30) evaluating mortality reduction may report an ARR of 15% (95% CI -3% to 33%; p = 0.08). Although statistically non-significant, it cannot exclude a transformative clinical benefit.
Parametric versus Non-Parametric Statistical Tests
Selecting the correct statistical test depends on:
Data Type : Continuous (interval/ratio), Ordinal (ranked/Likert scale), or Categorical (nominal).
Distribution : Normal (Gaussian bell curve) versus Non-Normal (skewed).
Number of Groups : Two groups versus three or more groups.
Sample Pairing : Independent (unpaired) versus Matched/Repeated measures (paired).
The Master Statistical Selection Matrix
Research Question Parametric Test; (Normal Distribution) Non-Parametric Test; (Skewed / Ordinal)
Compare 2 Independent Groups ; (e.g., Drug vs Placebo SBP) Unpaired Student's t-test (Independent samples) Mann-Whitney U test ; (Wilcoxon rank-sum test)
Compare 2 Paired Observations ; (e.g., Patient SBP Pre- vs Post-treatment) Paired Student's t-test Wilcoxon signed-rank test
Compare 3 or More Independent Groups ; (e.g., Statin A vs Statin B vs Diet) One-Way ANOVA ; (Analysis of Variance) Kruskal-Wallis test
Compare 3 or More Paired Groups ; (e.g., Pain score at 0, 4, 12 weeks) Repeated Measures ANOVA Friedman test
Correlation between 2 Continuous Variables ; (e.g., Age vs Bone mineral density) Pearson Correlation Coefficient (r) Spearman Rank Correlation (rho)
Compare Proportions in Categorical Data ; (e.g., 30-day mortality in 2 arms) Chi-Squared (χ²) Test Fisher's Exact Test ; (Mandatory when any expected cell count < 5)